211At及131I标记尼妥珠单抗的荷瘤小鼠体内治疗研究

doi:10.7538/tws.2022.35.03.0209

摘要/Abstract

摘要： 以靶向表皮生长因子受体(EGFR)的尼妥株单抗(nimotuzumab)为载体，开展²¹¹At和¹³¹I一步法标记流程的建立和对荷U87MG胶质瘤裸鼠的初步治疗研究。结果表明，标记率约95%，在磷酸缓冲液（PBS）和10%胎牛血清（FBS）中能保持一定稳定性；瘤内注射24 h后，药物在肿瘤的放射性摄取率仍然能保持在（28.2±4.7）%ID·g^-1；¹³¹I/²¹¹At-ATE-nimotuzumab均可对U87MG实体瘤的生长产生明显的抑制作用，且呈剂量相关性；整个治疗过程中，药物对荷瘤鼠体重无明显影响并且有效地延长了生存时间；相较而言，20 μCi的²¹¹At-ATE-nimotuzumab治疗组荷瘤小鼠中位生存时间长于200 μCi¹³¹I-ATE-nimotuzumab治疗组荷瘤小鼠的中位生存期，分别为35 d和31.6 d。该工作进一步确定了α核素²¹¹At在放射性靶向治疗研究中的潜力，为相关药物的临床前基础研究提供了重要参考。

关键词: ²¹¹At, ¹³¹I, 放射性靶向治疗, 尼妥珠单抗

Abstract: Using nimotuzumab targeting epidermal growth factor receptor (EGFR) as carrier, we have established a one-step labeling process for ²¹¹At and ¹³¹I and performed a preliminary treatment study on tumor-bearing mice. The labeling rate both were about 95%, and related radiolabeling complexes could maintain stability in PBS and FBS. The distribution showed that tumor uptake was still maintained to （28.2±4.7） %ID·g^-1 after 24 h at intratumoral injection. The therapeutic effect of ¹³¹I/²¹¹At -ATE-nimotuzumab in U87MG glioma-bearing nude mice was further evaluated. The two labeled drugs can significantly inhibit the growth of solid tumors in a dose-dependent manner with no significant effect on the body weight of mice, effectively prolonging the survival time of subjects. In comparison, the median survival time of tumor-bearing mice in the ²¹¹At-ATE-nimotuzumab group at 20 μCi was longer than that in the ¹³¹I-ATE-nimotuzumab group at 20 μCi (35 days and 31.6 days). This work further confirmed that the α-nuclide ²¹¹At has great potential in the research of radioactive targeted therapy, and can provide an important reference for the preclinical basic research of related drugs.

Key words: ²¹¹At, ¹³¹I, radioactive targeted therapy, nimotuzumab

刘葳豪, 马欢, 李飞泽, 李鸿岩, 兰图, 廖家莉, 秦芝, 刘宁, 杨远友. ²¹¹At及¹³¹I标记尼妥珠单抗的荷瘤小鼠体内治疗研究[J]. 同位素, 2022, 35(3): 209-216.

LIU Weihao, MA Huan, LI Feize, LI Hongyan, LAN Tu, LIAO Jiali, QIN Zhi, LIU Ning, YANG Yuanyou. Preliminary Treatment Study of ²¹¹At and ¹³¹I Labeled Nimotuzumab in Tumor-bearing Mice[J]. Journal of Isotopes, 2022, 35(3): 209-216.

参考文献

［1］James S, Bednarz B, Benedict S, et al. Current Status of radiopharmaceutical therapy［J］. International Journal of Radiation Oncology, Biology, Physics, 2021, 109(4): 891-901.
［2］Jadvar H. Targeted radionuclide therapy: an evolution toward precision cancer treatment［J］. American Journal of Roentgenology, 2017, 209(2): 277-288.
［3］Sapienza M T, Willegaignon J. Radionuclide therapy: current status and prospects for internal dosimetry in individualized therapeutic planning［J］. Clinics (Sao Paulo), 2019, 74: e835.
［4］Goldsmith S J. Targeted radionuclide therapy: a historical and personal review［J］. Seminars in Nuclear Medicine, 2020, 50(1): 87-97.
［5］Silberstein E B. Radioiodine: the classic theranostic agent［J］. Seminars in Nuclear Medicine, 2012, 42(3): 164-70.
［6］Bruchelt G, Klingebiel T, Treuner J. Radiolabeled metaiodobenzylguanidine (mibg) in diagnosis and therapy of neuroblastoma-results from basic research［J］. International Journal of Oncology, 1995, 6: 705-712.
［7］Ferris T, Carroll L, Jenner S, et al. Use of radioiodine in nuclear medicine-A brief overview［J］. Journal of Labelled Compounds & Radiopharmaceuticals, 2021, 64(3): 92-108.
［8］Uccelli L, Martini P, Cittanti C, et al. Therapeutic radiometals: worldwide scientific literature trend analysis (2008-2018)［J］. Molecules, 2019, 24(3):1-14.
［9］Makvandi M, Dupis E, Engle J W, et al. Alpha-emitters and targeted alpha therapy in oncology: from basic science to clinical investigations［J］. Target Oncology, 2018, 13(2): 189-203.
［10］Lyczko M, Pruszynski M, Majkowska-Pilip A, et al. 211At labeled substance P(5-11) as potential radiopharmaceutical for glioma treatment［J］. Nuclear Medicine and Biology, 2017, 53: 1-8.
［11］Aneheim E, Lindegren S, Jensen H, et al Astatine-211 labeling: a study towards automatic production of astatinated antibodies［J］. Journal of Radioanalytical and Nuclear Chemistry, 2014, 303(1): 979-983.
［12］Zalutsky M R, Pruszynski M. Astatine-211: production and availability［J］. Current Radio Pharmaceuticals, 2011, 4(3): 177-185.
［13］Nagao Y, Yamaguchi M, Watanabe S, et al. Astatine-211 imaging by a Compton camera for targeted radiotherapy［J］. Applied Radiation and Isotopes, 2018, 139: 238-243.
［14］Harari D, Yarden Y. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer［J］. Oncogene, 2000, 19: 6102-6114.
［15］Wada T, Qian X, Greene M I. Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function［J］. Cell, 1990, 61(7): 1339-1347.
［16］Reddy B K, Lokesh V, Vidyasagar M S, et al. Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: a randomized, open-label, phase Ⅱb, 5-year study in Indian patients［J］. Oral Oncology, 2014, 50(5): 498-505.
［17］Mazorra Z, Chao L, Lavastida A, et al. Nimotuzumab: beyond the EGFR signaling cascade inhibition［J］. Seminars in Oncology, 2018, 45(1-2): 18-26.
［18］Torres L A, Coca M A, Batista J F, et al. Biodistribution and internal dosimetry of the 188Re-labelled humanized monoclonal antibody anti-epidemal growth factor receptor, nimotuzumab, in the locoregional treatment of malignant gliomas［J］. Nuclear Medicine Communications, 2008, 29(1): 66-75.
［19］Kameswaran M, Samuel G, Dev S H,et al. 131I-Nimotuzumab-A potential radioimmunotherapeutic agent in treatment of tumors expressing EGFR［J］. Applied Radiation and Isotopes, 2015, 102: 98-102.
［20］Izquierdo S V, Muniz H S, Vazquez B H, et al. Biodistribution and tumor uptake of ⁶⁷Ga-Nimotuzumab in a malignant pleural mesothelioma xenograft［J］. Molecules, 2018, 23(12): 1-12.
［21］Tang Y, Hu Y, Liu W, et al. A radiopharmaceutical-［89Zr］Zr-DFO-nimotuzumab for immunoPET with epidermal growth factor receptor expression in vivo［J］. Nuclear Medicine and Biology, 2019, 70: 23-31.
［22］Liu W, Ma H, Tang Y, et al. One-step labelling of a novel small-molecule peptide with astatine-211: preliminary evaluation in vitro and in vivo［J］. Journal of Radioanalytical and Nuclear Chemistry, 2018, 316(2): 451-456.
［23］Kim Y S, Brechbiel M W. An overview of targeted alpha therapy［J］. Tumor Biology, 2012, 33(3): 573.
［24］Zalutsky M R, Reardon D A, Akabani G, et al. Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with ²¹¹At-labeled chimeric antitenascin monoclonal antibody 81C6［J］. Journal of Nuclear Medicine, 2008, 49(1): 30-48.
［25］Pruszyn′ski M, Bilewicz A, Zalutsky M R. Preparation of Rh［16aneS4-diol］²¹¹At and Ir［16aneS4-diol］²¹¹At complexes as potential precursors for astatine radiopharmaceuticals［J］. Part Ⅰ: Synthesis. Bioconjugate Chem, 2008, 19: 958-965.

[1]	初剑, 曹石巍, 陈德胜, 吴晓蕾, 王洁茹, 田伟, 黄清钢, 殷小杰, 谈存敏, 史克亮, 范芳丽, 秦芝, 白静. 干馏法从铀的裂变产物中分离¹³¹I[J]. 同位素, 2021, 34(6): 581-587.
[2]	邵武国;郭宏利;秦红斌;马红利. 高精度放射性药液自动分装系统的研制[J]. 同位素, 2019, 32(6): 395-402.
[3]	赵禹;刘向红;张玉龙;李海颖. 医用同位素生产堆应急停堆系统设计研究[J]. 同位素, 2019, 32(2): 128-132.
[4]	蹇源;周志军;卓连刚;赵鹏;廖伟;王关全;刘宁. 寡聚对苯乙炔与多肽拮抗剂RM26的偶联及¹³¹I标记研究[J]. 同位素, 2016, 29(3): 158-163.
[5]	马欢;唐禹;杨远友;刘宁;廖家莉;杨吉军. ¹³¹I标记新型小分子肽VP2[J]. 同位素, 2016, 29(1): 1-5.
[6]	孙祥敏;张云;张先;杨薇薇;蔡海燕. 碘［¹³¹I］爱克妥昔单抗注射液细菌内毒素检查方法建立[J]. 同位素, 2015, 28(3): 135-139.
[7]	邢兰兰;陈松;李亚明. 乳头状甲状腺癌术后复发的相关因素分析[J]. 同位素, 2014, 27(1): 22-27.
[8]	何锦秀;颜兵;史育红;董延武. 中美甲状腺摄¹³¹I率计算方法一致性研究[J]. 同位素, 2012, 25(2): 94-97.
[9]	韩云峰;童良前;兰琼;朱小华;陈璟;赵明. 血清TgAb和TPOAb水平对Graves甲亢患者¹³¹I治疗后甲减发生的影响[J]. 同位素, 2012, 25(1): 53-57.
[10]	刘宁;杨远友;廖家莉;金建南. 近年来²¹¹At放射性药物研究的新进展[J]. 同位素, 2011, 24(增刊): 36-44.
[11]	殷艳海;赵明;童良前;韩云峰. ¹³¹I治疗对SD大鼠血清降钙素水平的影响[J]. 同位素, 2011, 24(4): 225-228.
[12]	卢霞 ;王荣福 ;张春丽 . 新型多肽示踪剂¹³¹I-RRL肿瘤分子显像研究[J]. 同位素, 2011, 24(3): 177-181.
[13]	卢霞 ;王荣福 ;闫平 ;周颖明 ;张一帆 . Octreotide的¹³¹I标记及Graves 眼病炎症细胞的体外摄取[J]. 同位素, 2011, 24(2): 94-97.
[14]	刘侃峰;张彩霞. ¹³¹I-组胺-吲哚美辛对大鼠Lewis肺癌的SPECT显像及疗效观察 [J]. 同位素, 2010, 23(3): 173-176.

²¹¹At及¹³¹I标记尼妥珠单抗的荷瘤小鼠体内治疗研究

Preliminary Treatment Study of ²¹¹At and ¹³¹I Labeled Nimotuzumab in Tumor-bearing Mice

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 14

编辑推荐

Metrics